Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Accumulated Expenses: 2015-2020

Historic Accumulated Expenses for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to $7.3 million.

  • Outlook Therapeutics' Accumulated Expenses rose 63.83% to $7.3 million in Q2 2020 from the same period last year, while for Jun 2020 it was $7.3 million, marking a year-over-year increase of 63.83%. This contributed to the annual value of $4.6 million for FY2019, which is 28.42% down from last year.
  • As of Q2 2020, Outlook Therapeutics' Accumulated Expenses stood at $7.3 million, which was down 1.81% from $7.5 million recorded in Q1 2020.
  • Outlook Therapeutics' Accumulated Expenses' 5-year high stood at $8.3 million during Q2 2016, with a 5-year trough of $4.5 million in Q2 2019.
  • Its 3-year average for Accumulated Expenses is $5.6 million, with a median of $5.1 million in 2018.
  • Per our database at Business Quant, Outlook Therapeutics' Accumulated Expenses tumbled by 32.09% in 2018 and then skyrocketed by 63.83% in 2020.
  • Outlook Therapeutics' Accumulated Expenses (Quarterly) stood at $7.3 million in 2016, then declined by 25.93% to $5.4 million in 2017, then decreased by 16.87% to $4.5 million in 2018, then increased by 1.81% to $4.6 million in 2019, then spiked by 63.83% to $7.3 million in 2020.
  • Its Accumulated Expenses stands at $7.3 million for Q2 2020, versus $7.5 million for Q1 2020 and $4.6 million for Q4 2019.